Business
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration fieldLonza to
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration fieldLonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes (\"NDEs\"), set to be integrated into the clinical development program of PrimeC by NeuroSenseLonza's Dev-on-Demand solution to enable NeuroSense to access Lonza's process development with rapid initiation, execution, and delivery of workBASEL, Switzerland and CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (\"NeuroSense\"), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases, announced a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS. \n\n \n \n \n \n \n \n\n \nThis agreement provides NeuroSense with access to Lonza's unparalleled, state-of-the-art extracellular vesicles expertise and capabilities quickly and on an 'on-demand' basis, without further commitments. NeuroSense will leverage its extensive experience in biomarker utilization in neurodegenerative diseases. Lonza will provide the development, optimization, and qualification of a method measuring biomarkers from NDEs, which will be integrated into the development of NeuroSense's lead product candidate for ALS, PrimeC.\nDavide Zocco, Head of Exosomes Development, Lonza, commented: \"Lonza has made significant investments in the exosome field over the last decade, including the acquisition of Exosomics, reflecting our commitment to enable innovators to advance their therapies. Our 'Dev-on-Demand' solution provides NeuroSense with access to expert scientists working in state-of-the-art laboratories for their development activities. The team and platform make Lonza the partner of choice for NeuroSense to identify exosomes-based biomarkers.\" \nAlon Ben-Noon, NeuroSense's CEO, added: \"We believe this collaboration could be a game-changer for the ALS and neurodegeneration field, as findings in such biomarkers may advance early diagnosis and treatment, as well as expedite the regulatory pathway for new treatments for the millions of people who suffer from neurodege...